Therapeutic Focus

Establishing a pipeline of innovative medicines for the treatment of
Asia-prevalent cancers

Leveraging the team’s decades of experience in clinical development, AUM will initially focus on indications, but not limited to breast cancer, gastric cancer, hepatocellular carcinoma, head and neck cancer and prostate cancer.
Leveraging the team’s decades of experience in clinical development, AUM will initially focus on indications, but not limited to breast cancer, gastric cancer, hepatocellular carcinoma, head and neck cancer and prostate cancer.
With such a broad range of tumour types, AUM will rationally design intra-pipeline combinatorial treatments. With these treatments, AUM can achieve asset specific scientific differentiation.
With such a broad range of tumour types, AUM will rationally design intra-pipeline combinatorial treatments. With these treatments, AUM can achieve asset specific scientific differentiation.

Contact us directly for more information on our business development strategy.

AUM will embed trial digitalization from day one of clinical development

AUM’s precision medicine approach aims to reduce clinical trial times and patient numbers

Fewer than 20% of newly approved medicines in 2017 were available in emerging markets, specifically Asia1

1 IQVIA Oncology trend report 2018

CAREERS

AUM is building its team and is interested to hear from candidates. To view our current job openings, please visit our LinkedIn page or email us.

CONTACT US

  • Level 40
    Ocean Financial Centre
    10 Collyer Quay
    Singapore
    049315
    Tel: +65 6808 6034
    Fax: +65 6808 6699